Back to Search
MOSHE TALPAZ, MD
MD
Medical Oncology Physician
NPI: 1801972773IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
4301086684(MI)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
4301086684(MI)
Education
OTHER
Class of 1975
Research & Publications (20)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
PMID 16775234·N Engl J Med·2006
3-trial
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
PMID 16144928·Clin Cancer Res·2005
3-trial
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
PMID 19458059·Clin Cancer Res·2009
8-other
Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain.
PMID 18305550·Leukemia·2008
8-other
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
PMID 18577747·J Natl Cancer Inst·2008
7-preclinical
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
PMID 18754032·Leukemia·2008
3-trial
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
PMID 17971485·Blood·2008
8-other
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
PMID 18235045·Blood·2008
8-other
Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
PMID 19254887·Clin Lymphoma Myeloma·2008
6-review
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
PMID 17932248·Blood·2008
3-trial
The fine tuning of therapy for chronic myeloid leukemia and upcoming challenges.
PMID 19254883·Clin Lymphoma Myeloma·2008
8-other
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
PMID 17202319·Blood·2007
7-preclinical
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
PMID 16990591·Blood·2007
3-trial
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
PMID 17264298·Blood·2007
3-trial
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
PMID 18067005·Leuk Lymphoma·2007
6-review
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
PMID 17342766·Cancer·2007
8-other
Degrasyn activates proteasomal-dependent degradation of c-Myc.
PMID 17440106·Cancer Res·2007
7-preclinical
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
PMID 17179059·Ann Intern Med·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1500 EAST MEDICAL CENTER DR, 7TH FLOOR C.S. MOTT CHILDREN'S HOSPITAL
ANN ARBOR, MI 48109 - Phone
- (734) 936-9814
Quick Facts
- NPI
- 1801972773
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 51
- Publications
- 20
Are you this provider?
Claim Your Profile